company background image
ENOV logo

Enovis NYSE:ENOV Stock Report

Last Price

US$45.50

Market Cap

US$2.6b

7D

2.8%

1Y

-19.4%

Updated

27 Aug, 2024

Data

Company Financials +

Enovis Corporation

NYSE:ENOV Stock Report

Market Cap: US$2.6b

ENOV Stock Overview

Operates as a medical technology company focus on developing clinically differentiated solutions worldwide.

About the company

ENOV fundamental analysis
Snowflake Score
Valuation6/6
Future Growth0/6
Past Performance0/6
Financial Health3/6
Dividends0/6

Rewards

Trading at 83.5% below our estimate of its fair value
Trading at good value compared to peers and industry
Analysts in good agreement that stock price will rise by 50.1%

Risk Analysis

Shareholders have been diluted in the past year

Enovis Corporation Competitors

LivaNova

NasdaqGS:LIVN

US$2.5b

Envista Holdings

NYSE:NVST

US$3.2b

Omnicell

NasdaqGS:OMCL

US$2.1b

Tandem Diabetes Care

NasdaqGM:TNDM

US$2.9b

Price History & Performance

Summary of all time highs, changes and price drops for Enovis
Historical stock prices
Current Share PriceUS$45.50
52 Week HighUS$65.03
52 Week LowUS$39.98
Beta2.01
11 Month Change-5.41%
3 Month Change-8.01%
1 Year Change-19.41%
33 Year Change-68.51%
5 Year Change-42.05%
Change since IPO-27.78%

Recent News & Updates

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Aug 20
It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Recent updates

It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Aug 20
It's A Story Of Risk Vs Reward With Enovis Corporation (NYSE:ENOV)

Enovis Languishing Despite Respectable Performance

Jul 15

Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Jun 07
Here's Why Enovis (NYSE:ENOV) Can Afford Some Debt

Enovis: Solid Growth, But Unstable Financial Footing

May 05

Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Apr 22
Enovis Corporation (NYSE:ENOV) Might Not Be As Mispriced As It Looks

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Feb 12
Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Is Enovis (NYSE:ENOV) Using Too Much Debt?

Jan 14
Is Enovis (NYSE:ENOV) Using Too Much Debt?

Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Dec 18
Investors Holding Back On Enovis Corporation (NYSE:ENOV)

Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Nov 05
Calculating The Fair Value Of Enovis Corporation (NYSE:ENOV)

Enovis Making Good Choices, But Not Seeing The Rewards

Sep 27

Is Enovis (NYSE:ENOV) A Risky Investment?

Sep 22
Is Enovis (NYSE:ENOV) A Risky Investment?

Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Aug 03
Estimating The Intrinsic Value Of Enovis Corporation (NYSE:ENOV)

Enovis Corporation: Things Are Looking Good As Guidance Is Raised

Jul 18

We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Jun 20
We Think Enovis (NYSE:ENOV) Has A Fair Chunk Of Debt

Enovis Corporation Q4 2022 Earnings Preview

Feb 22

Is Enovis (NYSE:ENOV) A Risky Investment?

Feb 22
Is Enovis (NYSE:ENOV) A Risky Investment?

Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Jan 25
Is Enovis Corporation (NYSE:ENOV) Worth US$60.5 Based On Its Intrinsic Value?

Enovis Corporation reports Q3 earnings beat; updates FY22 guidance

Nov 02

Is Enovis (NYSE:ENOV) A Risky Investment?

Oct 19
Is Enovis (NYSE:ENOV) A Risky Investment?

Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?

Sep 14
Is Enovis Corporation (NYSE:ENOV) Trading At A 27% Discount?

Enovis launches augmented reality system ARVIS for use in hip, knee surgery

Jul 19

Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly

Jul 05
Here's Why Enovis (NYSE:ENOV) Can Manage Its Debt Responsibly

Enovis announces CFO transition

Jun 30

Enovis: Medtech Leftover Of Colfax With Some To Prove

May 23

As The Colfax Chapter Ends, Both ESAB And Enovis Have Something To Prove

Apr 05

Is Colfax (NYSE:CFX) Using Too Much Debt?

Feb 20
Is Colfax (NYSE:CFX) Using Too Much Debt?

With EPS Growth And More, Colfax (NYSE:CFX) Is Interesting

Jan 05
With EPS Growth And More, Colfax (NYSE:CFX) Is Interesting

Shareholder Returns

ENOVUS Medical EquipmentUS Market
7D2.8%2.1%0.6%
1Y-19.4%10.2%22.9%

Return vs Industry: ENOV underperformed the US Medical Equipment industry which returned 11.6% over the past year.

Return vs Market: ENOV underperformed the US Market which returned 24.9% over the past year.

Price Volatility

Is ENOV's price volatile compared to industry and market?
ENOV volatility
ENOV Average Weekly Movement4.9%
Medical Equipment Industry Average Movement8.6%
Market Average Movement6.3%
10% most volatile stocks in US Market15.1%
10% least volatile stocks in US Market3.1%

Stable Share Price: ENOV has not had significant price volatility in the past 3 months.

Volatility Over Time: ENOV's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19956,550Matt Trerotolawww.enovis.com

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.

Enovis Corporation Fundamentals Summary

How do Enovis's earnings and revenue compare to its market cap?
ENOV fundamental statistics
Market capUS$2.55b
Earnings (TTM)-US$107.11m
Revenue (TTM)US$1.91b

1.3x

P/S Ratio

-23.7x

P/E Ratio

Is ENOV overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ENOV income statement (TTM)
RevenueUS$1.91b
Cost of RevenueUS$788.55m
Gross ProfitUS$1.13b
Other ExpensesUS$1.23b
Earnings-US$107.11m

Last Reported Earnings

Jun 28, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.92
Gross Margin58.80%
Net Profit Margin-5.60%
Debt/Equity Ratio40.9%

How did ENOV perform over the long term?

See historical performance and comparison